A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

被引：20
作者：
Jurczak, Wojciech [1 ]
Zinzani, Pier Luigi [2 ]
Hess, Georg [3 ]
Gaidano, Gianluca [4 ]
Provencio, Mariano [5 ]
Nagy, Zsolt [6 ]
Robak, Tadeusz [7 ]
Maddocks, Kami J. [8 ]
Buske, Christian [9 ]
Ambarkhane, Sumeet [10 ]
Brugger, Wolfram [10 ]
Dirnberger-Hertweck, Maren [10 ]
Tillmanns, Sascha [10 ]
Weirather, Johannes [10 ]
Blum, Kristie [11 ]
机构：
[1] Jagiellonian Univ Med Coll, Dept Hematol, Krakow, Poland
[2] Univ Bologna, Ist Ematol, Bologna, Italy
[3] Johannes Gutenberg Univ Mainz, Dept Hematol Med Oncol & Pneumol, Mainz, Germany
[4] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy
[5] Univ Autonoma Madrid, Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, Madrid, Spain
[6] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary
[7] Med Univ Lodz, Dept Hematol, Lodz, Poland
[8] Ohio State Univ, Dept Internal Med, Arthur G James Comprehens Canc Ctr, Wexner Med Ctr, Columbus, OH 43210 USA
[9] Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany
[10] MorphoSys AG, Planegg, Germany
[11] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124297
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4078
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Long Term Follow-up Results of Brl-201 Phase I Study, a Crispr-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma
    Zheng, Biao
    Hu, Yongxian
    Zhang, Jiqin
    Zhang, Mingming
    Li, Wei
    Wu, Wenjun
    Cui, Jiazhen
    Wei, Guoqing
    Du, Bing
    Liu, Mingyao
    Huang, He
    [J]. BLOOD, 2023, 142
  • [42] Long term follow-up results of BRL-201 phase I study, a CRISPR-based non-viral PD-1 locus specific integrated anti-CD19 CAR-T cells in treating relapsed or refractory non-Hodgkin's lymphoma
    Zheng, Biao
    Hu, YongXian
    Zhang, Jiqin
    Zhang, Mingming
    Li, Wei
    Wu, Wenjun
    Cui, Jiazhen
    Wei, Guoqing
    Du, Bing
    Liu, Mingyao
    Huang, He
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] SC-gtCAR19, a Non-Viral Genome Targeting Anti-CD19 CAR-T Candidate in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Updated Results from Long-Term Follow-up
    Wang, Hui
    Gao, Ying
    Zhang, Ding
    Zheng, Yan
    Hu, Xingxing
    Gao, Qiuying
    Niu, Ben
    Hou, Limin
    Wang, Ling
    Zhang, Weihua
    Zhang, Yi
    Ru, Xingli
    Li, Le
    Peng, Zuohan
    Wang, Yi
    [J]. BLOOD, 2022, 140 : 4623 - 4624
  • [44] Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
    Younes, Anas
    Gordon, Leo
    Kim, Stella
    Romaguera, Jorge
    Copeland, Amanda R.
    Farial, Silvana de Castro
    Kwak, Larry
    Fayad, Luis
    Hagemeister, Frederick
    Fanale, Michelle
    Lambert, John
    Bagulho, Teresa
    Morariu-Zamfir, Rodica
    [J]. BLOOD, 2009, 114 (22) : 243 - 243
  • [45] Final Results of a Single Arm Phase III Multicenter, Open-Label Study of Rituximab Administered by Faster Infusion in Patients with Previously Untreated Diffuse Large-B Cell (DLBCL) or Follicular Non-Hodgkin's Lymphoma (FL)
    Dakhil, Shaker R.
    Hermann, Robert
    Chai, Akiko
    Hurst, Deborah
    Fine, Gregg
    Richards, Paul
    [J]. BLOOD, 2011, 118 (21) : 1162 - 1163
  • [46] Phase I study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma
    Shi, Y-K.
    Song, Y.
    Qin, Y.
    Zhou, K.
    Gao, Y.
    Wang, M.
    Wang, P.
    Yin, Q.
    Zhao, F.
    Ma, G.
    Li, F.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S652 - S652
  • [47] Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
    Kurzrock, Razelle
    Voorhees, Peter M.
    Casper, Corey
    Furman, Richard R.
    Fayad, Luis
    Lonial, Sagar
    Borghaei, Hossein
    Jagannath, Sundar
    Sokol, Lubomir
    Usmani, Saad
    van de Velde, Helgi
    Qin, Xiang
    Qi, Ming
    Cornfeld, Mark J.
    van Rhee, Frits
    [J]. BLOOD, 2011, 118 (21) : 1693 - 1693
  • [48] A multicenter phase II study of iodine-131 anti-B1 antibody (Bexxar) in patients (pts) with chemotherapy-relapsed/refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma (NHL)
    Kaminski, MS
    Vose, J
    Saleh, M
    Lister, A
    Knox, S
    Crowther, D
    Zelenetz, AD
    Colcher, D
    Wahl, R
    [J]. BLOOD, 1997, 90 (10) : 2268 - 2268
  • [49] C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up
    Li, Ping
    Yu, Wen-Juan
    Zhou, Lili
    Yang, Min
    Ye, Shiguang
    Zhu, Judy
    Huang, Jiaqi
    Zhang, Yan
    Li, Lanfang
    Zhao, Jing
    Zhu, Kevin
    Li, Jing
    Zheng, Chengxiao
    Lan, Liping
    Wan, Hui
    Yao, Yihong
    Zhang, Huilai
    Zhou, Daobin
    Jin, Jie
    Liang, Aibin
    [J]. BLOOD, 2023, 142
  • [50] PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis
    Siegel, D. S. D.
    Martin, T.
    Wang, M.
    Vij, R.
    Lonial, S.
    Kukreti, V.
    Bahlis, N. J.
    Alsina, M.
    Somlo, G.
    Buadi, F.
    Reu, F. J.
    Song, K. W.
    Kunkel, L. A.
    Wong, A.
    Vallone, M.
    Orlowski, R. Z.
    Stewart, A. K.
    Singhal, S.
    Jagannath, S.
    Jakubowiak, A. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345